WO2017172602A1 - Granulate formulation of 5-methy|-1-pheny|-2(1h)-pyridone and method of making the same - Google Patents
Granulate formulation of 5-methy|-1-pheny|-2(1h)-pyridone and method of making the same Download PDFInfo
- Publication number
- WO2017172602A1 WO2017172602A1 PCT/US2017/024280 US2017024280W WO2017172602A1 WO 2017172602 A1 WO2017172602 A1 WO 2017172602A1 US 2017024280 W US2017024280 W US 2017024280W WO 2017172602 A1 WO2017172602 A1 WO 2017172602A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formulation
- tablet
- amount
- glidant
- total weight
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the disclosure relates to granulate formulations of pirfenidone and methods of making granulate formulations of pirfenidone.
- 5-methyl-l-phenyl-2-(lH)-pyridone (also referred to as pirfenidone) is a non-peptide synthetic molecule with a molecular weight of 185.23 daltons. Its chemical elements are expressed as C12H11NO, and its structure is known. Pirfenidone has anti-fibrotic properties via: decreased TNF-a expression, decreased PDGF expression, and decreased collagen expression.
- pirfenidone One important use of pirfenidone is known to be providing therapeutic benefits to patients suffering from fibrosis conditions such as Hermansky-Pudlak Syndrome (HPS) associated pulmonary fibrosis and idiopathic pulmonary fibrosis (IPF).
- HPS Hermansky-Pudlak Syndrome
- IPF idiopathic pulmonary fibrosis
- pirfenidone may safely slow or inhibit the progressive enlargement of fibrotic lesions, remove pre-existing fibrotic lesions, and prevent formation of new fibrotic lesions following tissue injuries.
- Pirfenidone is a potent inhibitor of fibrogenic cytokines and TNF-a. It is well documented that pirfenidone inhibits excessive biosynthesis or release of various fibrogenic cytokines such as TGF- ⁇ , bFGF, PDGF, and EGF. Zhang S et al., Australian and New England Journal Ophthalmology, 26; S74-S76, 1998. Experimental reports also show that pirfenidone blocks the synthesis and release of excessive amounts of TNF-a from
- a granulate formulation of pirfenidone can include granules of pirfenidone and glidant and optionally one or more additional pharmaceutically acceptable excipients admixed with the granules.
- a method of making a granulate formulation of 5-methyl-l-phenyl-2-(lH)-pyridone can include mixing the 5-methyl-l-phenyl-2- (lH)-pyridone and intragranular excipients in a fluid bed granulator to form granules, wherein the granules comprise a glidant; and optionally adding one or more extragranular excipients to the granules to form the granulate formulation.
- the glidant can be included intragranularly in an amount of at least 1% by weight based on the total weight of the formulation.
- the formulation can include an intragranular glidant and an extragranular disintegrant.
- the formulation can include granules with pirfenidone, filler, binder, and glidant.
- the formulation can further include in some
- disintegrant lubricant, and further glidant as extragranular components added to granules.
- a tablet can comprise the formulation of any of the foregoing embodiments or embodiments disclosed herein.
- the tablet can consist of the formulation of any of the foregoing embodiments or embodiments disclosed herein.
- the tablet can consist essentially of the formulation of any of the foregoing embodiments or embodiments disclosed herein.
- Figure 1 is a schematic illustration of a process of forming a granulate formulation and film coated tablets in accordance with an embodiment of the disclosure
- Figure 2A is a photograph of a granulator bowl after processing a formulation without intragranular glidant
- Figure 2B is a photograph of a granulator bowl after processing a formulation with intragranular glidant in accordance with an embodiment of the disclosure
- Figure 3 is a graph illustrating the differences in particle size distribution of pirfenidone supplied from two different sources, Source 1 and Source 2;
- Figure 4A is scanning electron microscope images of pirfenidone supplied from Source 2;
- Figure 4B is scanning electron microscope images of pirfenidone supplied from Source l ;
- Figure 5 is a graph illustrating the correlation between disintegration time and tablet core solid fraction for a formulation in accordance with embodiments of the disclosure
- Figure 6 is a graph illustrating the correlation between disintegration time and tablet core thickness for three dosage strengths of a formulation in accordance with embodiments of the disclosure
- Figure 7 is a graph illustrating the effect of compression pressure on tensile strength of a compressed dosage form in accordance with an embodiment of the disclosure
- Figure 8 is a graph illustrating the effect of solid fraction percentage on tensile strength of a compressed dosage form in accordance with an embodiment of the disclosure
- Figure 9 is a graph of percent drug substance dissolved as a function of time for dissolution of 267 mg commercial pirfenidone capsules in 900 mL HCl 0.1 N, acetate pH 4.5, or phosphate pH 6.8;
- Figure 10 is a graph of percent drug substance dissolved as a function of time for dissolution of pirfenidone tablets in accordance with embodiments of the disclosure, having dosage strengths of 267 mg, 534 mg, and 801 mg in 900 mL HCl 0.1N;
- Figure 11 is a graph of percent drug substance dissolved as a function of time for dissolution of pirfenidone tablets in accordance with embodiments of the disclosure, having dosage strengths of 267 mg, 534 mg, and 801 mg in 900 mL acetate at pH 4.5;
- Figure 12 is a graph of percent drug substance dissolved as a function of time for dissolution of pirfenidone tablets in accordance with embodiments of the disclosure, having dosage strengths of 267 mg, 534 mg, and 801 mg in 900 mL phosphate at pH 6.8;
- Figure 13 is a graph of percent drug substance dissolved as a function of time for dissolution of pirfenidone tablets in accordance with embodiments of the disclosure, having dosage strengths of 267 mg, 534 mg, and 801 mg in 900 mL distilled water;
- Figure 14 is a graph of percent drug substance dissolved as a function of time for dissolution of 267 mg pirfenidone tablets in accordance with an embodiment of the disclosure, in 1000 mL distilled water;
- Figure 15 is a graph of percent drug substance dissolved as a function of time for dissolution of 534 mg pirfenidone tablets in accordance with an embodiment of the disclosure, in 1000 mL distilled water;
- Figure 16 is a graph of percent drug substance dissolved as a function of time for dissolution of 801 mg pirfenidone tablets in accordance with an embodiment of the disclosure, in 1000 mL distilled water;
- Figure 17 is a graph of percent drug substance dissolved as a function of time for dissolution of 267 mg pirfenidone tablets in accordance with an embodiment of the disclosure, in 900 mL HC1 0.1 N, acetate pH 4.5, or phosphate pH 6.8;
- Figure 18 is a graph of percent drug substance dissolved as a function of time for dissolution of 534 mg pirfenidone tablets in accordance with an embodiment of the disclosure, in 900 mL HC1 0.1 N, acetate pH 4.5, or phosphate pH 6.8;
- Figure 19 is a graph of percent drug substance dissolved as a function of time for dissolution of 801 mg pirfenidone tablets in accordance with an embodiment of the disclosure, in 900 mL HC1 0.1 N, acetate pH 4.5, or phosphate pH 6.8;
- Figure 20 is a graph of percent drug substance dissolved as a function of time for dissolution of 801 mg pirfenidone tablets in accordance with an embodiment of the disclosure, illustrating the effect of compression pressure and drug substance particle size on dissolution;
- Figure 21 is a graph of percent drug substance dissolved as a function of time for dissolution of 534 mg pirfenidone tablets in accordance with an embodiment of the disclosure, illustrating the effect of compression force on early stage dissolution;
- Figure 22 is a graph of percent drug substance dissolved as a function of time for dissolution of 267 mg pirfenidone tablets in accordance with an embodiment of the disclosure, illustrating the effect of compression force on early stage dissolution.
- Pirfenidone capsules are commercially available under the tradename Esbriet®, and are provided as a size #1 267 mg capsule.
- dosage amounts of 801 mg three times per day are often prescribed, requiring a patient to take 9 capsules per day.
- tablet formulations can represent a more patient friendly and compliant regimen.
- tablets can include 801 mg of pirfenidone, allowing for administration of one tablet, three times a day, or a total of three tablets. Tablets in accordance with embodiments of the disclosure can include from 100 mg to 1200 mg of pirfenidone.
- a dosage strength can be 200 mg, 267 mg, 534 mg, 600 mg, or 801 mg pirfenidone for a unit dose in accordance with an embodiment of the disclosure. Variations of the dosage strength can ease patient administration, for example, when dose titrating. Tablets in accordance with embodiments of the disclosure can be film coated. The film coating can be colored, for example, to distinguish between different dosage strengths.
- oral dosage forms of pirfenidone and particularly tablets, generally require high concentrations of pirfenidone in order to provide a tablet size that is of a manageable size for oral administration.
- Pirfenidone as an active ingredient has poor powder flowability characteristics, e.g. for formulation processing.
- formulation processes would utilize higher concentrations of excipients, particularly with difficult to process active ingredients.
- Such conventional formulation techniques cannot be utilized where a high concentration of active is needed. It has been discovered that the formulations disclosed herein provide a formulation that exhibits good flow properties during the granulation process, are capable of being compressed into tablets under standard compression conditions and result in stable tablets that resist cracking, yet maintain the desired dissolution properties.
- Pirfenidone is a highly crystalline, non-hygroscopic solid with a melting point range between 106 °C to 112 °C. It has been found that the particle size of pirfenidone can vary by suppliers. Referring to Figure 3, for example, it was found that pirfenidone from two different suppliers, Source 1 and Source 2, had distinct particle size distributions. In particular, pirfenidone from Source 1 was found to have a d9o particle size between 50 ⁇ to 64 ⁇ , while pirfenidone supplied from Source 2 was found to have a d9o particle size between 114 ⁇ to 151 ⁇ .
- Figures 4A and 4B are scanning electron microscopy images that further illustrate the differences in particle sizes observed with the differently sourced pirfenidone.
- pirfenidone consists of irregular shaped primary particles.
- the shape of the primary particles is comparable between the two sources.
- the smaller primary particles were found to have a tendency to form agglomerates.
- Higher levels of agglomerates were found in Source 1 as compared to Source 2 and in some batches of Source 1 drug substance, larger-sized agglomerates were found.
- methods of forming the granulate formulation in accordance with embodiments of the disclosure can also allow for subsequent formation of tablets that are free of micro-cracks and have sufficient hardness, despite variations in the particle size of the drug substance that may occur, e.g. from supplier to supplier. This can advantageously provide a more robust commercial scale process that can accommodate variations in the particle size without a need to change the tablet manufacturing process or tablet compression conditions.
- a granulate formulation can include granules which include pirfenidone and one or more pharmaceutically acceptable excipients.
- intragranular components refers to the ingredients included in the granule.
- the granulate formulation can include one or more excipients added to the granules as extragranular components.
- extragranular components refers to ingredients added to the as-formed granules.
- the formulation can include pirfenidone and a glidant as intragranular components.
- the formulations include an effective amount of intragranular glidant to improve powder and/or granule flow characteristics, for example, as measured by a flow function coefficient of about 4 to about 20, about 5 to about 15, or about 10 to about 14.
- the pre-granulation powders, granules, and/or granule formulation can have a flow function coefficient of about 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20.
- glidants are utilized only extragranularly to improve the flow of the as- formed granules in the tableting machine, but are not conventionally used or expected to improve flow of a drug substance during granulation.
- use of an intragranular glidant in the present formulation with pirfenidone can improve flow of the intragranular components in powder form, improve processing and flow of the granules, and improve flow of the granules with or without the addition of extragranular components during compression, such as in a tableting process.
- the formulations of the disclosure can be compressed, for example tableted, without the need for the addition of glidant as an extragranular component.
- excipients can be included in some embodiments.
- excipients include binders, fillers, disintegrants, lubricants, and further glidants, which can be provided as intragranular and/or extragranular components.
- a formulation includes pirfenidone, filler, binder, and a glidant as intragranular components, and a disintegrant, lubricant, and further glidant as extragranular components.
- weight by weight percentages (w/w%) of pirfenidone or excipients in the formulation as used herein refer to the weight based on the total weight of the core (e.g., tablet core) and exclude any weight of the exterior coatings.
- a formulation can include about 60 wt% to 95 wt% pirfenidone based on the total weight of the formulation.
- Other suitable amounts include about 70 wt% to about 95 wt%, about 65 wt% to about 90 wt%, about 80 wt% to about 95 wt%.
- the formulations can include pirfenidone in an amount of about 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92 94 and 95 wt% based on the total weight of the formulation.
- the unit doses can be provided with a dosage amount of pirfenidone in a range of about 100 mg to about 1100 mg.
- dosage strengths can include 200 mg, 267 mg, 534 mg, 600 mg, and 801 mg pirfenidone.
- dosage strengths can include 266 mg, 268 mg, 533 mg, 535 mg, and 800 mg pirfenidone.
- the unit dose is a compressed dosage form, for example, tablets.
- formulations of pirfenidone can include one or more excipients selected from the group consisting of binders, disintegrants, glidants, lubricants, and fillers. Excipients conventionally used as binders, fillers, glidants, lubricants, and fillers can be used in the formulations of the disclosure. Example listings of suitable excipients are provided below.
- the binder can be selected from the group consisting of hydroxymethyl cellulose, hydroxypropylcellulose, polyvinylpyrrolidone, calcium carbonate, dicalcium phosphate, carbomers, cellulose acetate phthalates, copovidone, hydroxypropyl methyl cellulose, ethylene glycol and vinyl glycol grafted copolymer, isomalt, poloxamer, polyethylene oxide,
- the binder can be included in an amount in a range of about 1 wt% to about 10 wt%, about 2 wt% to about 10 wt%, about 2 wt% to about 5 wt%, about 4 wt% to about 8 wt%, about 3 wt% to about 7 wt, and about 3 wt% to about 5 wt%, based on the total weight of the formulation.
- Other suitable amounts of binder include about 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, and 10 wt% based on the total weight of the formulation.
- binder amounts greater than 4 wt% can improve granule flowability and compaction behavior during tableting. Binder amounts ranging from about 3.9 wt% to about 4.8 wt% were found to improve compaction behavior of the granules without significant effect on the dissolution and disintegration characteristics of the formulation.
- the binder amounts are contemplated for any suitable binder, including polyvinylpyrrolidone.
- the disintegrant can be selected from the group consisting of agar-agar, algins, calcium carbonate, carboxmethylcellulose and salts thereof, cellulose, clays, corn starch, croscarmellose sodium, crospovidone, gums, methyl cellulose, polacrilin potassium, sodium alginate, cross- linked polyvinylpyrrolidone, sodium starch glycolate, starch, and combinations thereof.
- the disintegrant can be provided both within the granules (intragranularly) and extragranularly in a granulate formulation. Alternatively, the disintegrant can be included only intragranularly or only extragranularly.
- the disintegrant can be included in an amount in a range of about 0 wt% to about 10 wt%, 0 wt% to about 10 wt%, about 1 wt% to about 10 wt%, about 2 wt% to about 10 wt%, about 2 wt% to about 5 wt%, about 4 wt% to about 8 wt%, about 3 wt% to about 7 wt, and about 3 wt% to about 5 wt%, based on the total weight of the formulation.
- Other suitable amounts of disintegrant include about 0, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, and 10 wt%.
- the lubricant can be selected from the group consisting of agar, calcium stearate, ethyl oleate, ethyl laureate, glycerin, glyceryl behenate, glyceryl palmitostearate, hydrogenated vegetable oil, magnesium oxide, magnesium stearate, mannitol, poloxamer, glycols, sodium benzoate, sodium lauryl sulfate, sodium stearylstearate, sorbitol, stearic acid, talc, zinc stearate, and combinations thereof.
- the lubricant can be included in an amount in a range of about 0.05 wt% to about 2 wt%, about 0.1 wt% to about 1.8 wt%, about 0.5 wt% to about 1.5 wt%, about 1 wt% to about 2 wt%, about 0.05 wt% to about 0.5 wt%, about 0.1 wt% to about 0.8 wt%, or about 0.2 wt% to about 0.6 wt%, based on the total weight of the formulation.
- Suitable amounts of lubricant include about 0.05, 0.06, 0.07, 0.08, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.2, 1.4, 1.6, 1.8, and 2 wt%, based on the total weight of the formulation.
- the filler can be selected from the group consisting of calcium carbonate, calcium phosphate, dibasic calcium phosphate, calcium silicate, tribasic calcium sulfate, calcium carboxymethylcellulose and salts thereof, cellulose, dextrin derivatives, dextrin, dextrose, fructose, isomalt, kaolin, lactitol, lactose, magnesium carbonate, magnesium oxide, maltitol, maltodextrins, maltose, mannitol, microcrystalline cellulose, sodium bicarbonate, sodium carbonate, sorbitol, starch, sucrose, sugar, xylitol, and combinations thereof.
- the filler can be included in an amount in a range of about 2 wt% to about 30 wt%, about 4 wt% to about 20 wt%, about 10 wt% to about 30 wt%, about 2 wt% to about 10 wt%, and about 6 wt% to about 15 wt% based on the total weight of the formulation.
- Other suitable amounts include, about 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, and 30 wt% based on the total weight of the formulation.
- the filler amounts are contemplated for any suitable filler, including microcrystalline cellulose.
- the glidant can be selected from the group consisting of silica, fumed silica, silicified cellulose, sodium stearate, magnesium aluminum silicate, pyrogenic silica, hydrated sodium silioaluminate, cellulose, calcium phosphate, sodium lauryl sulfate, pregelatinized starch, talc, and physical or coprocessed combinations thereof.
- the glidant can be silica, and can be a hydrophilic fumed silica (a.k.a. colloidal silicon dioxide) .
- the glidant can be provided intragranularly and optionally extragranularly. In embodiments in which the glidant is provided both intragranularly and extragranularly, the glidant can be the same or different materials.
- the glidant can be included intragranularly in an amount, based on the total weight of the formulation, of at least about 1 wt%, at least about 1.5 wt%, at least about 2 wt%, at least about 2.5 wt%, at least about 3 wt%, at least about 3.5 wt% or at least about 4 wt%.
- the glidant when included intragranularly, can be in an amount of about 1 wt% to about 5 wt%, about 1.5 wt% to about 4.5 wt%, about 1.5 wt% to about 3.5 wt%, about 2 wt% to about 5 wt%, or about 1 wt% to about 4 wt%.
- intragranular glidant includes about 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, and 5 wt%, based on the total weight of the formulation.
- the glidant can be included extragranularly in an amount of about 0 wt% to about 5 wt%, 0 wt% to about 5 wt%, about 0.01wt% to about lwt%, about 0.03wt% to about 0.8 wt%, about 1 wt% to about 5 wt%, about 0.01 wt% to about 0.05 wt%, about 0.5 wt% to about 3 wt%, about 0.01 wt % to about 0.2 wt%, and about 0.05 wt% to about 1 wt%.
- extragranular glidant examples include about 0, 0.01, 0.02, 0.04, 0.06, 0.08, 0.1, 0.2, 0.4, 0.6, 0.8, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, and 5 wt%, based on the total weight of the formulation.
- the glidant amounts are contemplated for any suitable glidant, including silica.
- the extragranular components make up 10 wt% or less of a compressed formulation.
- the extragranular components can be 10 wt% or less, 10 wt% or less, 8 wt% or less, 7 wt% or less, 6 wt% or less.5 wt% or less, 4 wt% or less, 3 wt% or less, 2 wt% or less, or in a range of 0.01 wt% to 10 wt%, or 0.01 to 8 wt%, or 0.01 to 6 wt%, or 0.01 to 5 wt%, or 0.01 to 4 wt%, or 0.01 to 3 wt%, or 0.01 to 2 wt%, or 0.01 to 1 wt%, for example.
- the granulate formulation can be compressed into a tablet formulation. It has advantageously been discovered that tablets in accordance with the disclosure have drug release characteristics that correlate to the solid fraction. Solid fraction is a normalized process parameter calculated using the dimension of the tablet core (size of the compression tooling and thickness of the tablet), tablet weight, and true density (in contrast to bulk density) of the final blend. During a standard tablet compression operation, for a given dosage strength, all the other factors that define the solid fraction remain unchanged, with the exception of tablet thickness. Therefore, it has been determined that controlling the thickness of the tablet in a standard tablet compression operation can be used to target a predefined solid fraction during tablet compression, which in turn can be used to target a predefined pirfenidone release characteristic.
- the formulations are immediate release formulations.
- it can be desirable to have release of at least 80% of the drug substance in approximately 15 minutes.
- the compressed unit doses for example tablets, can have a solid fraction of at least 80%.
- the solid fraction is greater than 80%.
- the unit dose can have a solid fraction of about 80% to about 95%, about 85% to about 90%, about 90% to about 95%, greater than about 80% to 90%, about 81% to about 95%, and about 82% to about 94%.
- Other suitable solid fractions include 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, and 95%.
- a tablet in accordance with embodiments of the disclosure can have a thickness of about 2 mm to about 10 mm, about 2 mm to about 8 mm, about 3 mm to about 8 mm, and about 5 mm to about 10 mm. While the relationship between disintegration time and solid fraction generally has not varied depending on dosage amount in the embodiments tested, there has been some variation when utilizing tablet thickness as a parameter as shown in Figure 6.
- a process for forming a granulation in accordance with an embodiment of the disclosure can include mixing pirfenidone with one or more excipients using fluid bed granulation.
- the pirfenidone is mixed with a glidant using fluid bed granulation to form an granules.
- One or more excipients can be added to the granules (extragranularly). It has been advantageously found that use of a fluid bed granulation process can not only improve the processability of the formulation and toleration of pirfenidone particle size variation, but also provide improved tolerance of moisture content in the granulation.
- Formulations processed with conventional high- shear wet- granulation techniques were also found to be sensitive to changes in pirfenidone particle size distribution from different sources of pirfenidone, resulting in tablets with poor hardness values and oftentimes with microcracks forming in the tablets.
- formulations and methods in accordance with the disclosure were significantly less sensitive to pirfenidone particle size changes and moisture contents, as discussed in detail below.
- fluid bed granulation can be used. Fluid bed granulation can allow for a multiple-step wet granulation process performed in the same vessel, for example, to do one or more of pre-heat, granulate, and dry the powders.
- a method of making a formulation in accordance with the disclosure can include mixing pirfenidone and the intragranular excipients to form granules.
- the pirfenidone can be mixed with a glidant and a binder or binder solution or suspension to form granules.
- the granules can further include a filler mixed with the pirfenidone and glidant.
- the binder can be added as a solution or suspension. For example, the binder can be sprayed onto the pirfenidone and intragranular excipients.
- the binder can be provided, for example, as an aqueous solution, aqueous suspension, alcoholic solution, alcoholic suspension, or in an aqueous -alcoholic mixture, which can be a solution or suspension.
- the pirfenidone and intragranular excipients can be premixed prior to adding the binder.
- the granules can be dried to a target moisture content. For example, drying can be used to remove excess moisture that may have been introduced for example from a binder solution or suspension. Mixing and drying can be completed, for example, using a fluid bed granulator. The granules can then be screened in some embodiments. For example, a 2 mm screen can be used to aid in delumping of the granules. The dried and optionally screened granules can then be mixed with extragranular components. In an embodiment, this can include mixing the granules with a disintegrant and/or a further amount of glidant and/or a lubricant.
- the granules are mixed with a disintegrant and further amount of glidant and then the resulting mixture is mixed with a lubricant.
- the extragranular components are premixed and added to the granules in a single step.
- the method can optionally include heating the pirfenidone and excipients
- the preheating can aid in ensuring the mixture is in a fluidized, mixed state at the time of initiation of the spraying of the binder.
- the additions can be made simultaneously or serially.
- disintegrant, lubricant, and additional glidant are added extragranularly in a single step.
- disintegrant and glidant are added extragranularly in a first step and blended and then lubricant is added in a second step with further blending. Any suitable number of addition steps can be utilized.
- any or all of the drug substance and excipients of the formulation can be premixed and/or screened prior to granulation, for example, prior to charging the components into a granulator bowl.
- Premixing excipients at the given stages (for example) prior to loading the intragranular components into a mixer or granulator or adding the extragranular excipients to the granules can aid in ensuring good distribution of the components. Screening the excipients and/or premixtures prior to addition can further aid in delump the formulation components prior to loading into the granulator.
- the granulate formulation can be compressed into a compressed dosage form, e.g. a tablet.
- the formulation can be compressed using a compression pressure of about 50 MPa to about 500 MPa, about 100 MPa to about 400 MPa, about 200 MPa to about 300 MPa, about 100 MPa to about 170 MPa, and about 75 MPa to about 200 MPa.
- compression pressures include about 50, 55, 60, 65, 70 75, 80, 85, 90, 95, 00, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, and 500 MPa.
- a pre-compression force can be applied during the compression process (e.g. tablet making) for a time prior to application of the full main compression force.
- a pre-compression force of 20-30% of the main compression force can be applied.
- Compression force can affect the dissolution profile in the early stages of dissolution, generally within the initial 15 minutes.
- Figures 21 and 22 illustrate the changes in the early stage dissolution profile for two dosage strengths (534 mg tablet and 267 mg tablet, respectively) that can result from changing the compression force.
- the compressed dosage form is further coated with a film coating.
- tablets can be coated with a film coating.
- the coating is an immediate release coating.
- Exemplary coatings including, for example, Opadry II Yellow, Opadry II Pink, and Opadry II Purple. Coatings can be used, for example, to color the dosage form to identify by color, different dosage amounts. Coatings can also include light shielding agents in some embodiments, which can aid in maintaining the photostability of the dosage form.
- Any coatings and methods of coating compressed dosage forms can be used. Coatings can include one or more of titanium dioxide, iron oxide, talc, polyethylene glycol, and polyvinyl alcohol. The coatings can be applied as a solution using any suitable coating techniques.
- the coatings can be colored, for example, to differentiate dosage strengths.
- the coloring can be provided by a color iron oxide, for example, iron oxide black, iron oxide red, iron oxide yellow, and combinations thereof.
- the coatings add 1% to 5% weight to the formulation, for example, a tablet core. Any suitable coating amounts, coat weights, and added weight percentages can be used.
- formulations in accordance with embodiments of the disclosure can be compressed into a compressed dosage form without formation of microcracks and with suitable tablet physical properties including tensile strength.
- the methods and formulations in accordance with the disclosure are capable of tolerating differences in particle size of the drug substance.
- Figures 3 and 4 illustrate the differences in the particle size distribution of drug substance pirfenidone provided by two different suppliers.
- tabletability and compactability of the formulation can be affected by the differences in particle size.
- Formulations and methods of making such formulations, disclosed herein, for example, using fluid bed granulation can allow for the formation of compressed dosage forms having suitable physical characteristics despite the variability in particle size of the drug substance.
- Formulations in accordance with embodiments of the disclosure can comprise any combination of excipients disclosed herein.
- Formulations in accordance with embodiments of the disclosure can consist of any combination of excipients disclosed herein.
- Formulations in accordance with embodiments of the disclosure can consist essentially of any combination of excipients disclosed herein.
- a formulation in accordance with an embodiment of the disclosure can consist of pirfenidone, intragranular glidant, binder, and optionally one or more of a filler, disintegrant, further glidant, and lubricant.
- any of the foregoing embodiments of the granulate formulation can be provided in an oral dosage form.
- any of the granulate formulations disclosed herein can be provided as a compressed dosage form, e.g. a tablet.
- Tablets can comprise any combination of excipients disclosed herein.
- Tablets can consist of any combination of excipients disclosed herein.
- Tablets can consist essentially of any combination of excipients disclosed herein.
- tablets in accordance with embodiments of the disclosure can consist of pirfenidone, intragranular glidant, binder, and optionally one or more of a filler, disintegrant, further glidant, and lubricant.
- One embodiment of this disclosure provides methods for treating fibrotic conditions and other cytokine-mediated disorders. These methods comprise administering the formulation of this disclosure to a patient in need thereof.
- a patient "in need of pirfenidone therapy" is a patient who would benefit from administration of pirfenidone.
- the patient may be suffering from any disease or condition for which pirfenidone therapy may be useful in ameliorating symptoms.
- Pirfenidone is a known anti-fibrotic agent, so such disorders include fibrotic disorders, such as fibrotic disorders of the lung, kidney, liver, heart, or other organs. Other disorders that would benefit from therapy with pirfenidone include inflammatory disorders or autoimmune disorders.
- pirfenidone disorders that would benefit from therapy with pirfenidone include diseases that result in fibrosis, or where accompanying fibrosis is responsible in part for symptoms or complications of the disease, such as infarctions (tissue death), infection, cancer, cirrhosis, and the like.
- such diseases or conditions include pulmonary fibrosis, idiopathic pulmonary fibrosis, bronchiolitis obliterans, chronic lung transplant rejection, scleroderma, primary focal segmental glomerulosclerosis (FSGC) or membranoproliferative glomerulonephritis (MPGN), idiopathic interstitial pneumonia, interstitial lung disease in systemic sclerosis, a fibrosis condition of the lung, autoimmune lung diseases, benign prostate hypertrophy, coronary or myocardial infarction, atrial fibrillation, cerebral infarction, myocardiac fibrosis, musculoskeletal fibrosis, post-surgical adhesions, liver cirrhosis, renal fibrotic disease, fibrotic vascular disease, scleroderma, Hermansky-Pudlak syndrome, neurofibromatosis, Alzheimer's disease, diabetic retinopathy, and/or skin lesions, lymph node fibrosis associated with HIV, chronic infections
- autoimmune gastritis myasthenia gravis; autoimmune hemolytic anemia; autoimmune neutropenia; thrombocytopenia; pancreatic fibrosis; chronic active hepatitis including hepatic fibrosis; acute and chronic renal disease; renal fibrosis; diabetic nephropathy; irritable bowel syndrome; pyresis; restenosis; cerebral malaria; stroke and ischemic injury; neural trauma;
- Alzheimer's disease Huntington's disease; Parkinson's disease; acute and chronic pain; allergies, including allergic rhinitis and allergic conjunctivitis; cardiac hypertrophy, chronic heart failure; acute coronary syndrome; cachexia; malaria; leprosy; leishmaniasis; Lyme disease; Reiter's syndrome; acute synoviitis; muscle degeneration, bursitis; tendonitis; tenosynoviitis; herniated, ruptured, or prolapsed intervertebral disk syndrome; osteopetrosis; thrombosis; silicosis;
- pulmonary sarcosis bone resorption diseases, such as osteoporosis or multiple myeloma-related bone disorders
- cancer including but not limited to metastatic breast carcinoma, colorectal carcinoma, malignant melanoma, gastric cancer, and non-small cell lung cancer; graft- versus- host reaction; and auto-immune diseases, such as multiple sclerosis, lupus and fibromyalgia; AIDS and other viral diseases such as Herpes Zoster, Herpes Simplex I or II, influenza virus, Severe Acute Respiratory Syndrome (SARS) and cytomegalovirus; and diabetes mellitus.
- SARS Severe Acute Respiratory Syndrome
- the methods of the embodiments can be used to treat proliferative disorders (including both benign and malignant hyperplasias), including acute myelogenous leukemia, chronic myelogenous leukemia, Kaposi's sarcoma, metastatic melanoma, multiple myeloma, breast cancer, including metastatic breast carcinoma; colorectal, carcinoma; malignant melanoma; gastric cancer; non-small cell lung cancer (NSCLC); bone metastases, and the like; pain disorders including neuromuscular pain, headache, cancer pain, dental pain, and arthritis pain; angiogenic disorders including solid tumor angiogenesis, ocular neovascularization, and infantile hemangioma; conditions associated with the cyclooxygenase and lipoxygenase signaling pathways, including conditions associated with prostaglandin endoperoxide synthase-2
- IPF and scleroderma (or systemic sclerosis) associated interstitial lung disease (SSc-ILD) share overlapping pathologic pathways, most notably the activation and proliferation of fibroblasts, expression of fibrogenic cytokines and growth factors, and progressive interstitial fibrosis (Tzouvelekis et al. 2005; Castro and Jimenez 2010; Collard et al. 2010; Hummers 2010; van den Blink et al. 2010; Richards et al. 2012; Vij and Noth 2012).
- IPF and SSc-ILD also have biomarkers in common, including CCL 18, SP-A, SP D, KL 6, ICAM-1, VCAM 1, CCL 2, YKL-40, and vWF
- the patient may suffer from a disease selected from the group consisting of lung transplantation/chronic rejection, bronchiolitis obliterans, scleroderma, Primary focal segmental glomerulosclerosis (FSGS),
- a disease selected from the group consisting of lung transplantation/chronic rejection, bronchiolitis obliterans, scleroderma, Primary focal segmental glomerulosclerosis (FSGS),
- membranoproliferative glomerulonephritis MPGN
- Pneumotosis intestinalis Pneumotosis intestinalis
- Susac's syndrome microvascular impairment during chronic catheterization
- Hamartomatous disease blood spinal cord barrier dysfunction following spinal cord injury
- corneal perforation paraneoplastic disease
- rhabdomyolysis pulmonary capillaritis
- chronic hyperhomocysteinemia frontal-subcortical syndrome
- Wegener's granulomatosis acute intestinal microvascular dysfunction
- atherosclerotic disease keratitis
- episcleritis/scleritis cystic fibrosis
- polycystic kidney disease sickle cell disease
- dementia diabetic ulcer, microangiopathy or small vessel disease
- hypothyroidism thrombotic thrombocytopenic purpura
- ischemia-reperfusion injury haemolytic uraemic syndrome.
- the patient may suffer from a disease or disorder selected from one or more of "autoimmune" disorders of the central nervous system (CNS); a dementia that is not Alzheimer's Disease; a patient in need of pirfenidone therapy; a person who would benefit from pirfenidone administration optionally with the proviso that the patient is not suffering from idiopathic pulmonary fibrosis; Absence seizure; acquired immunodeficiency syndrome (AIDS) encephalitis; acute adult respiratory distress syndrome; acute coronary syndrome; acute intestinal microvascular dysfunction; acute myelogenous leukemia; acute or chronic pain; acute or chronic renal disease; acute synoviitis; acute tissue injury; adenovirus infection; adult respiratory distress syndrome; advanced benign prostate hypertrophy (BPH non-cancerous fibrous enlargement of the male prostate gland); AIDS; airway basement membrane collagen deposition; airway hyperresponsiveness; airway inflammation; airway remodeling; akinetic seizure; allergen-induced chronic air
- autoimmune lung diseases autoimmune neutropenia; bacterial infection; bacterial meningitis; benign and malignant hyperplasias; benign and malignant tumors lymphomas; benign or malignant hyperplasias; benign prostate hypertrophy; bleomycin-induced pulmonary fibrosis; Blood spinal cord barrier dysfunction following spinal cord injury; bone metastases; bone resorption diseases; brain concussion or contusion; brain edema; breast cancer; Bronchial asthma; bronchiolitis obliterans; bursitis; cachexia; cancer; cancer pain; cardiac fibrosis; cardiac hypertrophy; cardiovascular damage; carotid initimal hyperplasia after balloon angioplasty; cerebral infarction; cerebral malaria; Chagas disease; chronic active hepatitis; chronic bronchitis; chronic glomerulonephritis; chronic heart failure; chronic hyperhomocysteinemia; chronic lung transplant rejection; chronic myelogenous leukemia; chronic obstructive pulmonary disease; chronic thyroiditis; classical allergic response
- TNF-a inhibiting effect to the synthesis and release of TNF-a; insect bite; Insulin resistance; insulin resistance in type 2 diabetes; interstitial lung disease in systemic sclerosis; irritable bowel syndrome; ischemia-reperfusion injury; ischemic injury; Kaposi's sarcoma; keratitis;
- inflammatory disorders localized edema; lung sarcoidosis; lung transplantation/chronic rejection; lupus; Lyme disease; lymph node fibrosis associated with HIV; Lymphomas; malaria; malignant melanoma; membranoproliferative glomerulonephritis; metastatic breast carcinoma; metastatic melanoma; microangiopathy or small vessel disease; microangiopathy or small vessel disease that is not related to diabetes; microvascular disorder; microvascular impairment during chronic catheterization; microvascular integrity; mucus hypersecretion; multiple myeloma;
- multiple myeloma-related bone disorders multiple myeloma-related bone disorders; multiple sclerosis; muscle degeneration;
- musculoskeletal fibrosis myasthenia gravis; myocardial fibrosis; myoclonic seizure; myofacial pain syndrome; myofibroblast hypertrophy; neoplastic disease; neural trauma;
- neurofibromatosis neurologic injury; neuromuscular pain; non-small cell lung cancer; NULL; ocular neovascularization; organ hypoxia; Ormond's disease; osteoarthritis; osteopetrosis;
- osteoporosis other arthritic conditions; other fibrotic disorders; other viral diseases; pain; pain disorders; pancreatic damage; pancreatic fibrosis; paraneoplastic disease; Parkinson's syndrome; Parkinson's disease; Petit mal seizure; Pneumotosis intestinalis; polycystic kidney disease; postrenal dialysis syndrome; post-surgical adhesions; Pre-eclampsia; pressure bruises; prevent formation of new fibrotic lesions following tissue injuries; primary and secondary multiple sclerosis; primary focal segmental glomerulosclerosis; proliferative disorders; protozoal diseases; psoriasis; pulmonary asbestosis; pulmonary capillaritis; Pulmonary fibrosis caused by collagen vascular disease; Pulmonary fibrosis caused by hypersensitivity pneumonitis; Pulmonary fibrosis caused by inhalant exposure; Pulmonary fibrosis caused by sarcoidosis; pulmonary sarcosis pyresis; radiation and drug-induced lung fibro
- the patient may suffer from an atherosclerotic disease, including but not limited to atherosclerosis of the renal vasculature, cardiac vasculature, brain vasculature and/or peripheral vasculature.
- an atherosclerotic disease including but not limited to atherosclerosis of the renal vasculature, cardiac vasculature, brain vasculature and/or peripheral vasculature.
- the patient may suffer from thrombosis, an acute ischemic event, surgery, or an acute tissue injury.
- the dosing may be twice or three times daily, with one or more unit doses per intake.
- the total daily intake is at least 1200 mg pirfenidone.
- the total daily intake amount may vary, depending on the patient profile, including among other things the patient's demographic characteristics, physiological and genetic conditions, and disease prognosis. For example, a child or a senior person may be given a lower amount daily than that given to an ordinary adult.
- the anti-fibrotic activity of pirfenidone is demonstrated in in vivo animal fibrosis models, as well as in vitro cell culture studies with human or animal lung fibroblasts, dermal fibroblasts, and fibroblast-like cells.
- pirfenidone may be an effective agent for preventing and treating post-surgical adhesions, myocardial fibrosis, renal fibrosis, liver cirrhosis, atherosclerosis, and other fibrotic disorders.
- human mesenchymal-like cells including lung fibroblasts, skin fibroblasts, prostate stromal cells, and renal mesangial cells, etc.
- TGF- ⁇ , bFGF, PDGF, and EGF cytokine growth factors
- graded concentrations of pirfenidone were effective at levels which were ten to twenty times lower than those exerting any pharmacologically toxic effects on the cells.
- TGF- ⁇ is a potent growth-related peptide whose effects may be observed at femtomolar concentrations. It appears to be ubiquitous, and is a bifunctional regulator of cell proliferation in vitro. It acts either as a mitogen or a growth inhibitor depending on tissue concentration and the state of cell confluence (L.J. Striker et al., Lab. Invest. 64:446-456, 1991). In skin incisions, after attracting macrophages and fibroblasts, TGF- ⁇ enhances extracellular matrix formation by increasing transcription of genes for collagen and fibronectin, decreasing secretion of proteases, increasing secretion of protease inhibitors, and increasing transcription of cellular receptors for matrix proteins.
- pirfenidone may selectively arrest scar enlargement, and remodels or removes scar tissue or fibrosis.
- the dysfunction caused by fibrotic lesions may be ameliorated by the reduction or removal of the fibrotic lesion following pirfenidone treatment.
- organ and tissue function can be restored, even after the presence of fibrosis for several years.
- pirfenidone When given immediately after an insult, such as trauma, infection, or allergy, to a tissue, pirfenidone also may prevent formation of excessive scar tissue, or fibrotic lesions, and thus help retain normal function and appearance of the tissue.
- Pirfenidone may cause removal of excessive collagenous fibrotic tissue by a phagocytic action of local fibroblasts. This has been observed by examination of histological sections of lung tissue under the light microscope from dogs, mice, rats, and hamsters with pulmonary fibrosis treated with pirfenidone, and also through the electron micrographs of histological sections of lung tissue taken from hamsters with experimentally-induced asbestosis that were treated with pirfenidone. No infiltration of inflammation-inducing neutrophils, PMN cells, monocytes, lymphocytes occurred.
- the clinical criteria for beneficial response during the first months on pirfenidone included reduction in incidence of coughs, reduction in supplemental oxygen requirements, increased exercise tolerance, reduced dyspnea during exercise, amelioration of cor pulmonale, resumption of normal daily tasks, body weight gain, and survival.
- pulmonary function as gauged by chest x-ray, spirometry, or CO diffusion (DLCO) showed little, if any, change.
- DLCO CO diffusion
- Martinet et al. (NE Jour. Med., vol 317, 202-209, 1987) have described an exaggerated release of PDGF by alveolar macrophages in patients with idiopathic pulmonary fibrosis.
- the in vitro demonstration of inhibition by pirfenidone of the mitogenesis and enhanced formation of collagen caused by growth factors (bFGF, PDGF, and TGF- ⁇ ) may partly explain the beneficial in vivo anti-fibrotic action of pirfenidone.
- Pirfenidone may induce a remodeling of skin fibrotic lesions to reduce or remove keloids, reduce or remove dermal scars, and remove or lessen the contractures of hypertrophic (post burn injury) scars. In a similar condition, pirfenidone also acts to inhibit post-operative surgical adhesions.
- the formulation of the present disclosure may be administered according to certain embodiments of this disclosure to treat patients suffering from the following disorders:
- Central Nervous System syndromes relapsing-remitting multiple sclerosis, primary and secondary multiple sclerosis, spinal multiple sclerosis, cerebral malaria, viral or bacterial infections of the CNS, bacterial meningitis, "autoimmune" disorders of the central nervous system (CNS), CNS stroke and infarction, brain edema, Parkinson's syndrome, Alzheimer's disease, amylotrophic lateral sclerosis (ALS), and brain concussion or contusion;
- Musculoskeletal syndromes rheumatoid arthritis, trauma-induced arthritis, arthritis caused by a microbial infection, or by a parasite, tendonitis, and, arthritis induced by medical products or drugs (including small synthetic molecules as well as purified natural or synthesized peptides or proteins);
- Pulmonary syndromes acute adult respiratory distress syndrome, asthma, allergic rhinitis, allergic conjunctivitis, chronic obstructive pulmonary disease (COPD), and lung sarcoidosis;
- Gastro-intestinal syndromes Crohn's disease, ulcerative colitis, and liver inflammatory disorders
- the formulation of the present disclosure may be administered according to other embodiments to treat patients suffering from the following disorders: pulmonary fibrosis, radiation and drug- induced lung fibrosis, hepatic fibrosis, cardiac fibrosis, keloid, post-surgical adhesions, benign prostate hypertrophy in humans, arteriosclerosis, dermal fibrosis, and coronary restenosis.
- Tablet formulations having good manufacturability were produced having the following components:
- Example 1 Both the formulation of Example 1 and the formulation of the comparative example (Table 2) were processed using fluid bed granulation. As illustrated in Figure 2A, the comparative example resulted in residual powder remaining stuck to the side walls of the fluid bed granulator. Such sticking of the powder is indicative of the cohesive nature of the intragranular formulation and was found to be an impediment to commercial scale processing of the formulation of the comparative example. By comparison, as shown in Figure 2B, the formulation of Example 1 did not have a significant amount of residual powder stuck to the side- walls of the fluid bed granulator, resulting in a granulate formulation that was capable of being processed on a commercial scale.
- Flow function coefficient is a measure of powder flow. Values less than about 4 are considered poor and sub-optimal for powder processing. Values between 4-10 are considered acceptable flow values for powder processing. Flow behavior was analyzed for pure pirfenidone (without excipients) and a binary powder mixture of pirfenidone and
- microcrystalline cellulose mixed with either about 1% by weight silica or about 2% by weight silica, as shown in Table 3 below.
- the components were mixed in a turbula mixer and the different flow properties of the blends were measured.
- Tablets were formed from the formulation of Example 1 by applying a compression force of approximately 100 to 170 MPA and utilizing a pre-compression force that was 20-30% of the main compression force. Such compression forces produced tablet cores of solid fraction values between 87% and 93% and tensile strength values greater than 1.6 MPa. The tablets showed good abrasion characteristics (abrasion less 0.5%).
- Figures 7 and 8 illustrate the tabletability and compactability profiles for tablets having dosage amounts of pirfenidone of 801 mg (triangle symbol), 267 mg (diamond symbol), and 534 mg (square symbol).
- Solid fraction is a normalized process parameter calculated using the dimensions of the tablet core (size of the compression tooling and thickness of the tablet), tablet weight and true density of the final blend.
- the dimensions of the tablet core size of the compression tooling and thickness of the tablet
- all the other factors that define the solid fraction remain unchanged, with the exception of tablet thickness. Therefore, controlling the thickness of the tablet can be used to target a predefined solid fraction during tablet compression.
- Literature studies have shown that tablet solid fraction may have a strong influence on the mechanical strength (or hardness) of a resulting tablet core as well as its disintegration characteristics (Hancock et al., "The relative densities of pharmaceutical powders, blends, dry granulations, and immediate-release tablets," Pharm. Technol. 2003;27(4):64 -80).
- the relationship between the solid fraction (normalized tablet thickness) and the disintegration characteristics of the tablet are independent of the tablet mechanical strength.
- Figure 5 illustrates the correlation of the disintegration time to the solid fraction percentage
- Figure 6 illustrates the correlation of disintegration time to tablet core thickness. Identification of this relationship between tablet core thickness and drug release characteristics advantageously provides for control of a drug release properties by readily measureable and controllable parameter - tablet thickness.
- Croscarmellose sodium Croscarmellose sodium
- the film-coated tablets met the bioequivalence criteria of 90% confidence interval (80.00% to 125.00%) when compared to the capsules in the fasted state, based on AUCo ⁇ , AUCo-24 and C max .
- the film coated tablets met the bioequivalence criteria when compared to the capsules in the fed state with regard to AUCo- ⁇ and AUCo-24, but for C max the upper bound of 90% confidence interval was slightly outside the limit of 125.00%.
- AUC 0 .co area under the curve from zero to infinity
- AUC 0 .24 area under the curve from zero to 24 hours
- CI confidence interval
- C max maximal concentration
- AUCo-co area under the curve from zero to infinity
- AUCo-24 area under the curve from zero to 24 hours
- CI confidence interval
- C max maximal concentration
- Comparative dissolution profiles of all three strengths are provided in three different media without surfactant, i.e., 0.1N HCl, acetate buffer pH 4.5, phosphate buffer pH 6.8, as well as in the proposed commercial dissolution medium (water). Profiles were recorded with the paddle apparatus (apparatus II) operated at 50 rpm. Twelve samples were measured in 900 mL of the dissolution media described above at 37°C.
- Figure 9 illustrates the dissolution profile of the hard capsule (267 mg) used in the bioequivalence study.
- Figures 10-13 illustrate the comparative dissolution profiles for the different tablet strengths tested in four different media: HCl 0.1 N; acetate buffer pH 4.5; phosphate buffer pH 6.8; and water, respectively.
- Dissolution in distilled water with an agitation of 75 rpm using rotating basket (Ph. Eur./USP apparatus I) or 50/75 rpm using paddles (Ph. Eur./USP apparatus II) results in a rapidly dissolving profile (>85% after 15 minutes) and shows an ascending profile between the start of the test up to 15 minutes by reaching a plateau by up to 15 -20 minutes for the 801 mg and faster for the other strengths. Under all working conditions a standard deviation around 1% to 3% can be observed after 15 minutes.
- Drug substance particle size in the formulations of the disclosure was not found to affect the dissolution of tablets formed form the formulations, where the tablets had the same solid fraction. Formulations with drug substance from two different sources were evaluated. The following tablet provides the particle size distribution information of the sources tested.
- DS Drug Substance
- PSD particle size distribution
- Table 10 Tablet Hardness as a Function of Compression Force for Tablets Having Pirfenidone with Different Particle Size Distributions
- Compression force can affect the dissolution profile in the early stages of dissolution, generally after less than 15 minutes.
- the impact of compression force on the dissolution of three dosage strengths (801 mg, 534 mg, and 267 mg) were studied over a range of 5 KN to 25 KN.
- the dissolution profile can be affected by the compression force and generally manifested in a change in the shape of the profile during early dissolution stages (between approximately 0-15 minutes).
- Figures 21 and 22 illustrate the changes in the early stage dissolution profile of 534 mg tablets and 267 mg tablets, respectively, that can result from changing the compression force.
- Tableting Tablet hardness Hardness N 120 170 200 Same settings of inlet air temperature and inlet air volumes were used in both granulation and drying phases. b The spray rate and inlet air flow volume were combined together into a nominal factor, and varied concurrently.
- Table 12 shows a summary of the effect on the material attributes of the resulting granules.
- DOE Design of Experiment
- FFC flow function coefficient
- LOD loss on drying.
- Table 13 shows a summary of the effect on material attributes of the tablet cores.
- AVG average
- DOE Design of Experiment
- Hard. tablet core hardness
- RSD relative standard deviation
- temp. temperature.
- a Approximate tensile strength 1.7 - 1.8 MPa.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Tropical Medicine & Parasitology (AREA)
- Dermatology (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Vascular Medicine (AREA)
Abstract
Description
Claims
Priority Applications (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2018551222A JP7456721B2 (en) | 2016-03-29 | 2017-03-27 | Granule formulation of 5-methyl-1-phenyl-2-(1H)-pyridone and method for producing the same |
MX2018011819A MX2018011819A (en) | 2016-03-29 | 2017-03-27 | Granulate formulation of 5-methy|-1-pheny|-2(1h)-pyridone and method of making the same. |
CN202210243714.XA CN114533688A (en) | 2016-03-29 | 2017-03-27 | Granular preparation of 5-methyl-1-phenyl-2- (1H) -pyridone and preparation method thereof |
EP21164970.2A EP3895696B1 (en) | 2016-03-29 | 2017-03-27 | Granulate formulation of 5-methyl-1-phenyl-2(1h)-pyridone and method of making the same |
AU2017241530A AU2017241530B2 (en) | 2016-03-29 | 2017-03-27 | Granulate formulation of 5-methyl-1-phenyl-2(1H)-pyridone and method of making the same |
CN201780019644.7A CN108883072A (en) | 2016-03-29 | 2017-03-27 | 5- methyl-1-phenyl-2- (1H)-pyridone granular preparation and preparation method |
ES17716354T ES2883595T3 (en) | 2016-03-29 | 2017-03-27 | Granulated formulation of 5-methyl-1-phenyl-2 (1H) -pyridone and method of its preparation |
EP17716354.0A EP3435985B1 (en) | 2016-03-29 | 2017-03-27 | Granulate formulation of 5-methyl-1-phenyl-2(1h)-pyridone and method of making the same |
KR1020187028305A KR102552615B1 (en) | 2016-03-29 | 2017-03-27 | Granulation formulation of 5-methyl-1-phenyl-2-(1H)-pyridone and preparation method thereof |
PL17716354T PL3435985T3 (en) | 2016-03-29 | 2017-03-27 | Granulate formulation of 5-methyl-1-phenyl-2(1h)-pyridone and method of making the same |
IL261745A IL261745B2 (en) | 2016-03-29 | 2018-09-13 | Granulate formulation of 5-methyl-1-phenyl-2(1h)-pyridone and method of making the same |
JP2022041514A JP2022087115A (en) | 2016-03-29 | 2022-03-16 | Granulate formulation of 5-methyl-1-phenyl-2(1h)-pyridone and method of making the same |
AU2022275529A AU2022275529A1 (en) | 2016-03-29 | 2022-11-25 | Granulate formulation of 5-methyl-1-phenyl-2(1H)-pyridone and method of making the same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662314933P | 2016-03-29 | 2016-03-29 | |
US62/314,933 | 2016-03-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2017172602A1 true WO2017172602A1 (en) | 2017-10-05 |
Family
ID=57575344
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2017/024280 WO2017172602A1 (en) | 2016-03-29 | 2017-03-27 | Granulate formulation of 5-methy|-1-pheny|-2(1h)-pyridone and method of making the same |
Country Status (13)
Country | Link |
---|---|
US (2) | US10188637B2 (en) |
EP (2) | EP3435985B1 (en) |
JP (2) | JP7456721B2 (en) |
KR (1) | KR102552615B1 (en) |
CN (2) | CN108883072A (en) |
AR (1) | AR107990A1 (en) |
AU (2) | AU2017241530B2 (en) |
CA (1) | CA2937365C (en) |
ES (1) | ES2883595T3 (en) |
IL (1) | IL261745B2 (en) |
MX (1) | MX2018011819A (en) |
PL (1) | PL3435985T3 (en) |
WO (1) | WO2017172602A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3511001A1 (en) | 2018-01-12 | 2019-07-17 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Pirfenidone-containing tablet and capsule formulation |
WO2021198253A1 (en) | 2020-04-01 | 2021-10-07 | Boehringer Ingelheim International Gmbh | Use of biomarkers in the treatment of fibrotic conditions |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20180100869A (en) * | 2017-03-02 | 2018-09-12 | 영진약품 주식회사 | Pharmaceutical composition of particle size controlled pirfenidone with improved compressibility and method for preparing the same |
EP3694491A1 (en) * | 2017-10-10 | 2020-08-19 | Capsugel Belgium NV | Gelling multiparticulates |
EP3494965B1 (en) * | 2017-12-11 | 2021-06-02 | Laurus Labs Limited | An improved process for the preparation of pirfenidone |
WO2020115774A1 (en) | 2018-12-06 | 2020-06-11 | Cipla Limited | High drug load extended release formulations |
CN114206341A (en) * | 2019-07-31 | 2022-03-18 | 豪夫迈·罗氏有限公司 | Novel pharmaceutical formulations |
WO2021057599A1 (en) * | 2019-09-26 | 2021-04-01 | 深圳先进技术研究院 | Application of pirfenidone in preparing medicament for preventing and treating rheumatoid arthritis |
CN111166748B (en) * | 2019-12-14 | 2022-06-21 | 深圳先进技术研究院 | Application of pirfenidone in preparation of angiogenesis promoting medicine |
WO2022172076A1 (en) * | 2021-02-09 | 2022-08-18 | DWIVEDI, Dr. Jayesh | Preparation of microwave dried novel co-processed excipient of sucrose and tablet formulation of canagliflozin tablets using co- processed excipient |
WO2023161668A1 (en) | 2022-02-28 | 2023-08-31 | Nuformix Technologies Limited | Compositions and methods for treatment of idiopathic pulmonary fibrosis |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3974281A (en) * | 1972-12-18 | 1976-08-10 | Affiliated Medical Research, Inc. | 5-Methyl-1-phenyl-2-(1H)-pyridone compositions and methods of use |
EP1356816A1 (en) * | 2001-01-29 | 2003-10-29 | Shionogi & Co., Ltd. | Medicinal preparation containing 5-methyl-1-phenyl-2-(1h)-pyridone as active ingredient |
WO2007038315A2 (en) * | 2005-09-22 | 2007-04-05 | Intermune, Inc. | Capsule formulation of pirfenidone and pharmaceutically acceptable excipients |
CN101972236A (en) * | 2010-10-13 | 2011-02-16 | 北京诚创康韵医药科技有限公司 | Sustained release preparation containing pirfenidone |
EP2735306A1 (en) * | 2011-07-19 | 2014-05-28 | Cell Therapy And Technology, S.A. De C.V. | Method for manufacturing a pharmaceutical composition in the form of extended-release tablets containing pirfenidone and use thereof in the regression of chronic renal insufficiency, breast capsular contracture and hepatic fibrosis in humans |
Family Cites Families (168)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4052509A (en) | 1972-12-18 | 1977-10-04 | Affiliated Medical Research, Inc. | Method for reducing serum uric acid levels |
US4042699A (en) | 1972-12-18 | 1977-08-16 | Affiliated Medical Research, Inc. | Method for reducing serum glucose levels |
DE3404810A1 (en) | 1984-02-10 | 1985-08-14 | Siemens AG, 1000 Berlin und 8000 München | WINDOW FUNCTION FOR AN APERTUR WINDOW |
CA1261835A (en) | 1984-08-20 | 1989-09-26 | Masaaki Toda | (fused) benz(thio)amides |
US4753801A (en) | 1985-10-25 | 1988-06-28 | Eli Lilly And Company | Sustained release tablets |
US5104648A (en) | 1989-02-02 | 1992-04-14 | Mallinckrodt Specialty Chemicals Company | High ibuprofen content granulations |
JPH02215719A (en) | 1989-02-15 | 1990-08-28 | Yamauchi Akitomo | Agent for repairing fibrosing lesion tissue and preventing fibrosing lesion |
US5275823A (en) | 1989-04-27 | 1994-01-04 | Smith Kline & French Laboratories Ltd. | Pharmaceutical compositions |
US5518729A (en) | 1989-11-22 | 1996-05-21 | Margolin; Solomon B. | Compositions and methods for reparation and prevention of fibrotic lesions |
US5716632A (en) | 1989-11-22 | 1998-02-10 | Margolin; Solomon B. | Compositions and methods for reparation and prevention of fibrotic lesions |
US5310562A (en) | 1989-11-22 | 1994-05-10 | Margolin Solomon B | Composition and method for reparation and prevention of fibrotic lesions |
US5861172A (en) | 1991-05-08 | 1999-01-19 | Laboratorios Beecham Sa | Pharmaceutical formulations of compacted granulates of β-lactam antibiotics |
US5534262A (en) | 1992-01-10 | 1996-07-09 | Dobrotvorsky; Anatoly E. | Pharmaceutical granulated composition and method for preparing same |
DK0636023T3 (en) | 1992-04-15 | 1999-12-06 | Alteon Inc | Process for spray drying aminoguanidine |
DE59209706D1 (en) | 1992-12-01 | 1999-07-08 | Spirig Ag | Medicines containing S (+) - ibuprofen |
WO1994026249A1 (en) | 1993-05-07 | 1994-11-24 | Margolin Solomon B | Compositions and methods for reparation and prevention of fibrotic lesions |
WO1995006462A1 (en) | 1993-08-30 | 1995-03-09 | Warner-Lambert Company | Tablet coating based on a melt-spun mixture of a saccharide and apolymer |
US5591766A (en) | 1993-12-03 | 1997-01-07 | Cheil Foods & Chemicals, Inc. | Solid oral formulations of pyridone carboxylic acids |
GB9325644D0 (en) | 1993-12-15 | 1994-02-16 | Smithkline Beecham Plc | Novel formulation |
US5639754A (en) | 1994-07-12 | 1997-06-17 | Janssen Pharmaceutica N.V. | Urea and thiourea derivatives of azolones |
US6107458A (en) | 1994-10-07 | 2000-08-22 | Fujisawa Pharmaceutical Co., Ltd. | Cyclic hexapeptides having antibiotic activity |
US6395303B1 (en) | 1996-06-10 | 2002-05-28 | Edward Mendell Co., Inc. | Process for preparing a directly compressible solid dosage form containing microcrystalline cellulose |
US5585115A (en) | 1995-01-09 | 1996-12-17 | Edward H. Mendell Co., Inc. | Pharmaceutical excipient having improved compressability |
GB9501127D0 (en) | 1995-01-20 | 1995-03-08 | Wellcome Found | Tablet |
US6090822A (en) | 1995-03-03 | 2000-07-18 | Margolin; Solomon B. | Treatment of cytokine growth factor caused disorders |
DK0837052T3 (en) | 1995-06-21 | 2007-01-02 | Shionogi & Co | Bicyclic amino derivatives and PGD2 antagonist containing them |
US5681382A (en) | 1995-08-22 | 1997-10-28 | Shin-Etsu Chemical Co., Ltd. | Rapidly soluble coating composition and method for preparing same |
AU709178B2 (en) | 1995-09-19 | 1999-08-26 | Intermune, Inc. | Inhibition of tumor necrosis factor alpha |
US5962478A (en) | 1995-09-19 | 1999-10-05 | Margolin; Solomon B. | Inhibition of tumor necrosis factor α |
US6852336B2 (en) | 1995-11-15 | 2005-02-08 | J. Rettenmaier & Soehne Gmbh + Co. Kg | Directly compressible high load acetaminophen formulations |
US6348216B1 (en) | 1996-06-10 | 2002-02-19 | Knoll Pharmaceutical Company | Ibuprofen and narcotic analgesic compositions |
US6361794B1 (en) | 1996-06-12 | 2002-03-26 | Basf Corporation | Method of making ibuprofen and narcotic analgesic composition |
DE19628617A1 (en) | 1996-07-16 | 1998-01-22 | Basf Ag | Direct tabletting aid |
US7179486B1 (en) | 1997-04-01 | 2007-02-20 | Nostrum Pharmaceuticals, Inc. | Process for preparing sustained release tablets |
TW580397B (en) | 1997-05-27 | 2004-03-21 | Takeda Chemical Industries Ltd | Solid preparation |
ATE241341T1 (en) | 1997-09-10 | 2003-06-15 | Takeda Chemical Industries Ltd | STABILIZED PHARMACEUTICAL COMPOSITION |
CN1195500C (en) | 1998-05-18 | 2005-04-06 | 武田药品工业株式会社 | Orally disintegrable tablet |
BR9910481A (en) | 1998-06-11 | 2001-01-09 | Upjohn Co | Pharmaceutical composition for non-continuous release tablet |
US6117451A (en) | 1998-08-25 | 2000-09-12 | Pharmalogix, Inc. | Direct compression metformin hydrochloride tablets |
US6599530B2 (en) | 1998-09-14 | 2003-07-29 | Orion Corporation | Oral compacted composition comprising catechol derivatives |
IT1311907B1 (en) | 1999-04-06 | 2002-03-20 | Zambon Spa | DEGLUTABLE TABLETS WITH HIGH CONTENT OF N-ACETYLCISTEIN. |
US6262072B1 (en) | 1999-10-12 | 2001-07-17 | Yung Shin Pharmaceutical Industrial Co. Ltd. | Orally administered antimicrobial pharmaceutical formulations of ciprofloxacin |
CZ300558B6 (en) | 1999-12-09 | 2009-06-17 | Reckitt Benckiser Healthcare (Uk) Limited | Tablet composition of non-steroidal antiphlogistic medicament and process for preparing thereof |
US6956044B1 (en) | 2000-02-21 | 2005-10-18 | Margolin Solomon B | Compositions and methods for treatment of epilepsy |
AU3402301A (en) | 2000-03-07 | 2001-09-17 | Ranbaxy Laboratories Limited | Azole compounds as therapeutic agents for fungal infections |
EP1269995A1 (en) | 2000-03-27 | 2003-01-02 | Kyowa Hakko Kogyo Co., Ltd. | Easy-to-take granule |
KR20030024799A (en) | 2000-07-20 | 2003-03-26 | 뉴로젠 코포레이션 | Capsaicin receptor ligands |
US20040034039A1 (en) | 2000-09-22 | 2004-02-19 | Yoshinori Nakano | Solid preparations |
MXPA03009353A (en) | 2001-04-12 | 2004-02-12 | Pharmacopeia Inc | Aryl and biaryl piperidines used as mch antagonists. |
WO2002087549A1 (en) | 2001-04-25 | 2002-11-07 | Taisho Pharmaceutical Co., Ltd. | Multiple unit type sustained-release tablets |
US6761905B2 (en) | 2001-05-01 | 2004-07-13 | Wei Ming Pharmaceutical Mfg. Co., Ltd. | Process for the preparation of direct tabletting formulations and aids |
AU2002352878B2 (en) | 2001-11-27 | 2007-11-22 | Merck Sharp & Dohme Corp. | 2-Aminoquinoline compounds |
ES2345044T3 (en) | 2002-02-01 | 2010-09-14 | Euro-Celtique S.A. | 2-PIPERAZIN-PIRIDINES USEFUL TO TREAT THE PAIN. |
US6974818B2 (en) | 2002-03-01 | 2005-12-13 | Euro-Celtique S.A. | 1,2,5-thiadiazol-3-YL-piperazine therapeutic agents useful for treating pain |
GB0209265D0 (en) | 2002-04-23 | 2002-06-05 | Novartis Ag | Organic compounds |
EP1515701B1 (en) | 2002-06-17 | 2014-09-17 | Inventia Healthcare Private Limited | Process for the manufacture of multilayer tablet compositions comprising thiazolidinedione and biguanide |
WO2004002983A2 (en) | 2002-06-28 | 2004-01-08 | Euro-Celtique, S.A. | Therapeutic piperazine derivatives useful for treating pain |
US7262194B2 (en) | 2002-07-26 | 2007-08-28 | Euro-Celtique S.A. | Therapeutic agents useful for treating pain |
US8268352B2 (en) | 2002-08-05 | 2012-09-18 | Torrent Pharmaceuticals Limited | Modified release composition for highly soluble drugs |
CA2496314A1 (en) | 2002-08-27 | 2004-03-11 | Intermune, Inc. | Methods of treating idiopathic pulmonary fibrosis |
CA2496577A1 (en) | 2002-08-28 | 2004-03-11 | Intermune, Inc. | Combination therapy for treatment of fibrotic disorders |
US7157462B2 (en) | 2002-09-24 | 2007-01-02 | Euro-Celtique S.A. | Therapeutic agents useful for treating pain |
JP2006505570A (en) | 2002-10-17 | 2006-02-16 | アムジエン・インコーポレーテツド | Benzimidazole derivatives and their use as vanilloid receptor ligands |
US7582635B2 (en) | 2002-12-24 | 2009-09-01 | Purdue Pharma, L.P. | Therapeutic agents useful for treating pain |
JP4542743B2 (en) | 2002-12-26 | 2010-09-15 | Kdl株式会社 | Solution pharmaceutical composition of pyridone derivatives |
US20060147528A1 (en) | 2003-02-28 | 2006-07-06 | Deepak Murpani | Extended release, multiple unit dosage forms of phenytoin sodium and processes for their preparation |
RS20050714A (en) | 2003-03-31 | 2008-04-04 | Pliva-Lachema A.S., | Pharmaceutical composition containing platinum co mplex as aktive substance and method of manufact uring thereof |
WO2004089344A1 (en) | 2003-04-01 | 2004-10-21 | Ohara Chmical Industries, Ltd. | Process for producing tablet |
US8507000B2 (en) | 2003-05-06 | 2013-08-13 | Nostrum Pharmaceuticals, Inc. | Controlled release formulation of erythromycin derivatives |
US20050008691A1 (en) | 2003-05-14 | 2005-01-13 | Arturo Siles Ortega | Bicalutamide compositions |
WO2005016241A2 (en) | 2003-05-16 | 2005-02-24 | Intermune, Inc. | Synthetic chemokine receptor ligands and methods of use thereof |
WO2004103296A2 (en) | 2003-05-16 | 2004-12-02 | Intermune, Inc. | Methods of treating idiopathic pulmonary fibrosis |
HUP0301537A3 (en) | 2003-06-03 | 2005-07-28 | Egis Gyogyszergyar Nyilvanosan | Deramcyclane fumarate tablets and process for producing them |
MY142655A (en) | 2003-06-12 | 2010-12-15 | Euro Celtique Sa | Therapeutic agents useful for treating pain |
WO2005004763A1 (en) | 2003-07-01 | 2005-01-20 | Pharmacia & Upjohn Company Llc. | Diffusion layer modulated solids |
US7632521B2 (en) | 2003-07-15 | 2009-12-15 | Eurand, Inc. | Controlled release potassium chloride tablets |
EA009480B1 (en) | 2003-07-24 | 2008-02-28 | Еуро-Селтик С. А. | Heteroaryl-tetrahydropiperidyl compounds useful for treating or prevention pain |
GEP20094676B (en) | 2003-07-24 | 2009-05-10 | Euro Celtique Sa | Piperidine compounds and pharmaceutical compositions containing them |
DE602004025244D1 (en) | 2003-08-01 | 2010-03-11 | Euro Celtique Sa | THERAPEUTIC AGENTS SUITABLE FOR THE TREATMENT OF PAIN |
DE602004017481D1 (en) | 2003-09-22 | 2008-12-11 | Euro Celtique Sa | THERAPEUTIC AGENTS SUITABLE FOR THE TREATMENT OF PAIN |
CN1856489A (en) | 2003-09-22 | 2006-11-01 | 欧洲凯尔特公司 | Phenyl-carboxamide compounds useful for treating pain |
US20050079221A1 (en) | 2003-10-10 | 2005-04-14 | Groenewoud Pieter Jurjen | Ibuprofen narcotic composition and method for making same |
WO2005039598A1 (en) | 2003-10-24 | 2005-05-06 | Intermune, Inc. | Method of treating alcoholic liver disease |
US7407973B2 (en) | 2003-10-24 | 2008-08-05 | Intermune, Inc. | Use of pirfenidone in therapeutic regimens |
EP1683788B1 (en) | 2003-11-14 | 2012-03-21 | Shanghai Genomics, Inc. | Derivatives of pyridone and use thereof |
US7592373B2 (en) | 2003-12-23 | 2009-09-22 | Boehringer Ingelheim International Gmbh | Amide compounds with MCH antagonistic activity and medicaments comprising these compounds |
RS50958B (en) | 2003-12-30 | 2010-10-31 | Euro-Celtique S.A. | Piperazines useful for treating pain |
SE0400235D0 (en) | 2004-02-06 | 2004-02-06 | Active Biotech Ab | New composition containing quinoline compounds |
US8642079B2 (en) | 2004-02-23 | 2014-02-04 | Hormos Medical Corporation | Solid formulations of ospemifene |
US7605176B2 (en) | 2004-03-06 | 2009-10-20 | Boehringer Ingelheim International Gmbh | β-ketoamide compounds with MCH antagonistic activity |
PE20110121A1 (en) | 2004-03-17 | 2011-02-28 | Novartis Ag | PHARMACEUTICAL COMPOSITIONS OF ALISKIREN |
WO2005115990A1 (en) | 2004-05-26 | 2005-12-08 | Eisai R & D Management Co., Ltd. | Cinnamide compound |
CA2566771A1 (en) | 2004-06-07 | 2005-12-22 | Wyeth | Sugar coatings and methods therefor |
BRPI0512900A (en) | 2004-06-30 | 2008-04-15 | Albemarle Corp | pharmaceutical composition comprising ibuprofen, process for preparing the ibuprofen-enriched granules and the dry granules made by this process |
WO2006080029A1 (en) | 2005-01-27 | 2006-08-03 | Alembic Limited | Extended release formulation of levetiracetam |
WO2006082499A1 (en) | 2005-02-03 | 2006-08-10 | Nycomed Pharma As | Melt granulation of a composition containing a calcium-containing compound |
US20070009591A1 (en) | 2005-07-07 | 2007-01-11 | Trivedi Jay S | ACE inhibitor formulation |
EP2305696A3 (en) | 2005-07-25 | 2011-10-12 | Intermune, Inc. | Macrocyclic inhibitors of Hepatitis C virus replication |
US20070203202A1 (en) | 2005-12-02 | 2007-08-30 | Robinson Cynthia Y | Methods of reducing adverse events associated with pirfenidone therapy |
EP1959944A1 (en) | 2005-12-15 | 2008-08-27 | Shionogi Co., Ltd. | A pharmaceutical composition comprising an amide derivative |
WO2007081341A1 (en) | 2006-01-11 | 2007-07-19 | Teva Phamaceutical Industries Ltd. | Controlled release formulation of divalproic acid and its derivatives |
FR2898056B1 (en) | 2006-03-01 | 2012-01-20 | Ethypharm Sa | SQUEEZE-RESISTANT TABLETS TO PREVENT UNLAWFUL MISUSE |
CZ300698B6 (en) | 2006-06-16 | 2009-07-22 | Zentiva, A. S. | Metformin-containing tablet |
CA2656019C (en) | 2006-06-28 | 2016-09-13 | Emisphere Technologies, Inc. | Gallium nitrate formulations |
US20080254118A1 (en) | 2007-04-11 | 2008-10-16 | Hans-Werner Wernersbach | Process for preparing pramipexole dihydrochloride tablets |
WO2008062446A2 (en) | 2006-09-14 | 2008-05-29 | Alembic Limited | An extended release composition of levetiracetam, which exhibits no adverse food effect |
CA2563690C (en) | 2006-10-12 | 2014-10-07 | Pharmascience Inc. | Pharmaceutical compositions comprising intra- and extra- granular fractions |
US8951562B2 (en) | 2006-11-10 | 2015-02-10 | Atacama Labs Oy | Method and apparatus or dry granulation |
CA2667654C (en) | 2006-12-18 | 2016-12-13 | Intermune, Inc. | Method of providing pirfenidone therapy to a patient |
EP1952803A1 (en) | 2007-01-23 | 2008-08-06 | KTB-Tumorforschungs GmbH | Solid pharmaceutical dosage form containing hydrogenated phospholipids |
US8389549B2 (en) | 2007-04-27 | 2013-03-05 | Purdue Pharma L.P. | Substituted pyridines useful for treating pain |
CA2833209C (en) | 2007-04-27 | 2016-06-28 | Purdue Pharma L.P. | Piperidine and piperazine compounds as trpv1 antagonists |
EP1987814A1 (en) | 2007-04-30 | 2008-11-05 | Exelgyn | Mifepristone pharmaceutical compositions and their methods of preparation |
US20080287508A1 (en) | 2007-05-18 | 2008-11-20 | Intermune, Inc. | Altering pharmacokinetics of pirfenidone therapy |
AU2008265595B2 (en) | 2007-06-20 | 2014-12-04 | PureTech LYT 100 Inc. | Substituted N-Aryl pyridinones as fibrotic inhibitors |
PT2170292E (en) | 2007-06-22 | 2014-03-06 | Bristol Myers Squibb Holdings Ireland | Tableted compositions containing atazanavir |
CN101801348A (en) | 2007-06-22 | 2010-08-11 | 百时美施贵宝公司 | tableted compositions containing atazanavir |
JP2010530892A (en) | 2007-06-22 | 2010-09-16 | ブリストル−マイヤーズ スクイブ カンパニー | Tablet composition containing atazanavir |
US20090131485A1 (en) | 2007-09-10 | 2009-05-21 | Concert Pharmaceuticals, Inc. | Deuterated pirfenidone |
DK2217241T3 (en) | 2007-11-07 | 2018-08-06 | Rigel Pharmaceuticals Inc | WATER GRANULATION USING A WATER COMPLEX GENERATOR |
JP2011518144A (en) | 2008-04-17 | 2011-06-23 | ファイザー・インク | 4-Benzylidene-3-methylpiperidine arylcarboxamide compounds useful as FAAH inhibitors |
EP2296659B1 (en) | 2008-06-05 | 2016-12-21 | Janssen Pharmaceutica, N.V. | Drug combinations comprising a DGAT inhibitor and a PPAR-agonist |
GB2460915B (en) | 2008-06-16 | 2011-05-25 | Biovascular Inc | Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor |
GB0813929D0 (en) | 2008-07-30 | 2008-09-03 | Glaxo Group Ltd | Novel method |
WO2010035282A1 (en) | 2008-09-24 | 2010-04-01 | Matrix Laboratories Limited | Pharmaceutical compositions comprising deferasirox |
US8759362B2 (en) | 2008-10-24 | 2014-06-24 | Purdue Pharma L.P. | Bicycloheteroaryl compounds and their use as TRPV1 ligands |
US8546388B2 (en) | 2008-10-24 | 2013-10-01 | Purdue Pharma L.P. | Heterocyclic TRPV1 receptor ligands |
US8703962B2 (en) | 2008-10-24 | 2014-04-22 | Purdue Pharma L.P. | Monocyclic compounds and their use as TRPV1 ligands |
WO2010048716A1 (en) | 2008-10-29 | 2010-05-06 | Pacific Therapeutics Ltd. | Composition and method for treating fibrosis |
US8778398B2 (en) | 2008-11-04 | 2014-07-15 | Jazz Pharmaceuticals, Inc. | Immediate release formulations and dosage forms of gamma-hydroxybutyrate |
US7566729B1 (en) | 2008-11-10 | 2009-07-28 | Intermune, Inc. | Modifying pirfenidone treatment for patients with atypical liver function |
US7635707B1 (en) | 2008-11-10 | 2009-12-22 | Intermune, Inc. | Pirfenidone treatment for patients with atypical liver function |
US20100166861A1 (en) | 2008-12-29 | 2010-07-01 | Kelly Noel Lynch | Pharmaceutical formulations of sevalamer, or salts thereof, and copovidone |
JP5583659B2 (en) | 2009-03-13 | 2014-09-03 | 富山化学工業株式会社 | 6-Fluoro-3-hydroxy-2-pyrazinecarboxamide-containing tablets and granulated powder |
WO2010135470A1 (en) | 2009-05-19 | 2010-11-25 | Intermune, Inc. | Pifenidone derivatives for treating bronchial asthma |
TWI434833B (en) | 2009-06-03 | 2014-04-21 | Intermune Inc | Improved method for synthesizing pirfenidone |
CN101921225B (en) | 2009-06-11 | 2013-04-03 | 北京凯得尔森生物技术有限公司 | Pirfenidone compound, preparation method and application thereof |
RS59599B2 (en) * | 2009-11-09 | 2023-03-31 | Wyeth Llc | Tablet formulations of neratinib maleate |
US7816383B1 (en) | 2009-12-04 | 2010-10-19 | Intermune, Inc. | Methods of administering pirfenidone therapy |
US8084475B2 (en) | 2009-12-04 | 2011-12-27 | Intermune, Inc. | Pirfenidone therapy and inducers of cytochrome P450 |
EP2338474A1 (en) * | 2009-12-23 | 2011-06-29 | Ratiopharm GmbH | Fusion tablet containing compacted sildenafil base |
IL210279A0 (en) | 2009-12-25 | 2011-03-31 | Dexcel Pharma Technologies Ltd | Extended release compositions for high solubility, high permeability acdtive pharmaceutical ingredients |
EP2359814A1 (en) | 2010-02-11 | 2011-08-24 | Laboratorios Liconsa, S.A. | Pharmaceutical mini-tablets for sustained release of flecainide acetate |
CA2789307A1 (en) | 2010-03-29 | 2011-10-06 | Hetero Research Foundation | Stable pharmaceutical composition of imatinib |
US8921373B2 (en) | 2010-06-22 | 2014-12-30 | Shionogi & Co., Ltd. | Compounds having TRPV1 antagonistic activity and uses thereof |
US9132132B2 (en) | 2010-09-02 | 2015-09-15 | Hetero Research Foundation | Pharmaceutical compositions of linezolid |
TR201011148A1 (en) | 2010-12-30 | 2012-07-23 | Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ | Levetiracetam pharmaceutical compositions. |
EP2663283B1 (en) | 2011-01-14 | 2017-05-10 | Bristol-Myers Squibb Company | High drug load tablet formulation of brivanib alaninate |
US10105356B2 (en) | 2011-01-31 | 2018-10-23 | Avalyn Pharma Inc. | Aerosol pirfenidone and pyridone analog compounds and uses thereof |
EP2677868B1 (en) | 2011-02-21 | 2020-01-15 | Hetero Research Foundation | Pharmaceutical compositions of maraviroc and process for the preparation thereof |
EP2683379A4 (en) | 2011-03-08 | 2014-10-01 | Auspex Pharmaceuticals Inc | Substituted n-aryl pyridinones |
WO2013022924A1 (en) | 2011-08-08 | 2013-02-14 | Teva Pharmaceutical Industries Ltd. | Pharmaceutical formulations |
CN102846555B (en) * | 2012-04-09 | 2014-06-25 | 珠海亿邦制药股份有限公司 | Solid preparation comprising pirfenidone as active component and application thereof |
EP2838380B1 (en) | 2012-04-20 | 2018-04-18 | DSM IP Assets B.V. | Solid, color-stable l-ascorbic acid compositions |
US20150224086A1 (en) | 2012-08-23 | 2015-08-13 | Hetero Research Foundation | Pharmaceutical Formulations of Rufinamide |
CA2819967C (en) | 2012-08-31 | 2016-03-22 | Intermune, Inc. | Use of pirfenidone concomitantly with ciprofloxacin |
CN102846569A (en) | 2012-09-06 | 2013-01-02 | 北京万全德众医药生物技术有限公司 | Drug composition containing pirfenidone, and preparation method thereof |
CA2888883A1 (en) | 2012-10-18 | 2014-04-24 | Abbvie Inc. | Formulations of pyrimidinedione derivative compounds |
DK2946780T3 (en) | 2013-01-15 | 2017-05-08 | Fujifilm Corp | TABLE CONTAINING 5-HYDROXY-1H-IMIDAZOLE-4-CARBOXAMIDE |
WO2014115082A1 (en) | 2013-01-22 | 2014-07-31 | Dr. Reddys Laboratories Limited | Pharmaceutical formulations of imatinib |
US20140234415A1 (en) | 2013-02-20 | 2014-08-21 | Abbvie Inc. | Tablet Dosage Forms |
NZ711179A (en) | 2013-03-08 | 2018-07-27 | Novartis Ag | Oral formulations of deferasirox |
GB201304699D0 (en) | 2013-03-15 | 2013-05-01 | Remedica Ltd | Pharmaceutical compositions |
CN103271886B (en) | 2013-05-29 | 2014-08-13 | 南京正大天晴制药有限公司 | Pirfenidone tablet and preparation method thereof |
MX2016002560A (en) | 2013-08-29 | 2016-10-26 | Teva Pharma | Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir and a monolithic tablet comprising darunavir and ritonavir. |
WO2015040093A1 (en) | 2013-09-20 | 2015-03-26 | Dsm Sinochem Pharmaceuticals Netherlands B.V. | Tablet comprising crospovidone |
JP6574415B2 (en) | 2013-10-07 | 2019-09-11 | ブリストル−マイヤーズ・スクイブ・ホールディングス・アイルランド・アンリミテッド・カンパニーBristol−Myers Squibb Holdings Ireland Unlimited Company | HIV preparations for atazanavir and cobicistat |
CN107205945A (en) | 2015-01-27 | 2017-09-26 | 詹森药业有限公司 | Dispersible composition |
-
2016
- 2016-07-28 CA CA2937365A patent/CA2937365C/en active Active
-
2017
- 2017-03-27 MX MX2018011819A patent/MX2018011819A/en unknown
- 2017-03-27 CN CN201780019644.7A patent/CN108883072A/en active Pending
- 2017-03-27 JP JP2018551222A patent/JP7456721B2/en active Active
- 2017-03-27 PL PL17716354T patent/PL3435985T3/en unknown
- 2017-03-27 EP EP17716354.0A patent/EP3435985B1/en not_active Revoked
- 2017-03-27 AU AU2017241530A patent/AU2017241530B2/en not_active Revoked
- 2017-03-27 WO PCT/US2017/024280 patent/WO2017172602A1/en active Application Filing
- 2017-03-27 ES ES17716354T patent/ES2883595T3/en active Active
- 2017-03-27 KR KR1020187028305A patent/KR102552615B1/en active IP Right Grant
- 2017-03-27 CN CN202210243714.XA patent/CN114533688A/en active Pending
- 2017-03-27 EP EP21164970.2A patent/EP3895696B1/en active Active
- 2017-03-28 US US15/472,222 patent/US10188637B2/en active Active
- 2017-03-28 AR ARP170100761A patent/AR107990A1/en unknown
-
2018
- 2018-04-30 US US15/967,415 patent/US20180243277A1/en not_active Abandoned
- 2018-09-13 IL IL261745A patent/IL261745B2/en unknown
-
2022
- 2022-03-16 JP JP2022041514A patent/JP2022087115A/en active Pending
- 2022-11-25 AU AU2022275529A patent/AU2022275529A1/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3974281A (en) * | 1972-12-18 | 1976-08-10 | Affiliated Medical Research, Inc. | 5-Methyl-1-phenyl-2-(1H)-pyridone compositions and methods of use |
EP1356816A1 (en) * | 2001-01-29 | 2003-10-29 | Shionogi & Co., Ltd. | Medicinal preparation containing 5-methyl-1-phenyl-2-(1h)-pyridone as active ingredient |
WO2007038315A2 (en) * | 2005-09-22 | 2007-04-05 | Intermune, Inc. | Capsule formulation of pirfenidone and pharmaceutically acceptable excipients |
CN101972236A (en) * | 2010-10-13 | 2011-02-16 | 北京诚创康韵医药科技有限公司 | Sustained release preparation containing pirfenidone |
EP2735306A1 (en) * | 2011-07-19 | 2014-05-28 | Cell Therapy And Technology, S.A. De C.V. | Method for manufacturing a pharmaceutical composition in the form of extended-release tablets containing pirfenidone and use thereof in the regression of chronic renal insufficiency, breast capsular contracture and hepatic fibrosis in humans |
Non-Patent Citations (7)
Title |
---|
CAIN ET AL., INTERNATIONAL JOURNAL IMMUNOPHARMACOLOGY, vol. 20, 1998, pages 685 - 695 |
HANCOCK ET AL.: "The relative densities of pharmaceutical powders, blends, dry granulations, and immediate-release tablets", PHARM. TECHNOL., vol. 27, no. 4, 2003, pages 64 - 80, XP055064508 |
L.J. STRIKER ET AL., LAB. INVEST., vol. 64, 1991, pages 446 - 456 |
MARTINET ET AL., NE JOUR. MED., vol. 317, 1987, pages 202 - 209 |
PITT ET AL.: "Compression prediction accuracy from small scale compaction studies to production presses", POWDER TECH., vol. 270, 2015, pages 490 - 493, XP029113870, DOI: doi:10.1016/j.powtec.2013.10.007 |
VAN BARNEVELD ET AL., AMER. REV. RESPR. DIS., vol. 135, 1987, pages 48 - 51 |
ZHANG S ET AL., AUSTRALIAN AND NEW ENGLAND JOURNAL OPHTHALMOLOGY, vol. 26, 1998, pages S74 - S76 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3511001A1 (en) | 2018-01-12 | 2019-07-17 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Pirfenidone-containing tablet and capsule formulation |
WO2021198253A1 (en) | 2020-04-01 | 2021-10-07 | Boehringer Ingelheim International Gmbh | Use of biomarkers in the treatment of fibrotic conditions |
Also Published As
Publication number | Publication date |
---|---|
IL261745B2 (en) | 2023-06-01 |
PL3435985T3 (en) | 2021-11-22 |
MX2018011819A (en) | 2019-07-04 |
JP7456721B2 (en) | 2024-03-27 |
ES2883595T3 (en) | 2021-12-09 |
JP2022087115A (en) | 2022-06-09 |
CN114533688A (en) | 2022-05-27 |
EP3895696B1 (en) | 2023-08-09 |
AU2017241530B2 (en) | 2022-12-15 |
KR20180123067A (en) | 2018-11-14 |
CN108883072A (en) | 2018-11-23 |
EP3435985A1 (en) | 2019-02-06 |
IL261745A (en) | 2018-10-31 |
KR102552615B1 (en) | 2023-07-06 |
CA2937365A1 (en) | 2016-12-22 |
AR107990A1 (en) | 2018-07-04 |
JP2019513145A (en) | 2019-05-23 |
EP3435985B1 (en) | 2021-05-12 |
EP3895696A1 (en) | 2021-10-20 |
AU2022275529A1 (en) | 2023-01-19 |
AU2017241530A1 (en) | 2018-10-04 |
US20170281609A1 (en) | 2017-10-05 |
US20180243277A1 (en) | 2018-08-30 |
US10188637B2 (en) | 2019-01-29 |
CA2937365C (en) | 2018-09-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2017241530B2 (en) | Granulate formulation of 5-methyl-1-phenyl-2(1H)-pyridone and method of making the same | |
AU2006295440B2 (en) | Capsule formulation of pirfenidone and pharmaceutically acceptable excipients | |
AU2013201986B2 (en) | Capsule Formulation Of Pirfenidone And Pharmaceutically Acceptable Excipients | |
AU2014240300C1 (en) | Capsule Formulation of Pirfenidone and Pharmaceutically Acceptable Excipients |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2018/011819 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 2018551222 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20187028305 Country of ref document: KR Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2017241530 Country of ref document: AU Date of ref document: 20170327 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2017716354 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2017716354 Country of ref document: EP Effective date: 20181029 |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17716354 Country of ref document: EP Kind code of ref document: A1 |